Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Ophthalmology
•
Vitreoretinal Diseases and Surgery
What has been your experience with controlling diabetic macular edema after switching to Eylea HD, especially when restricted to a q8w interval following the loading phase?
Related Questions
Is there a role for PDT in a young patient with PXE and bilateral CNVM who requires intravitreal anti-VEGF injections every 4 weeks and is beginning to develop atrophy?
How do you determine whether to switch to a different anti-VEGF agent or to Ozurdex after a patient with diabetic macular edema fails a series of Avastin?
When should surgical resection be considered for vasoproliferative tumors?
What factors influence the decision between anti-VEGF injections and surgical displacement with tPA for treating submacular hemorrhage in AMD patients?
How do you manage a situation where the lens optic shifts in front of the iris after a Yamane technique?
What’s your approach to managing postoperative inflammation and CME in high-risk patients after cataract surgery?
How do you typically manage the use of intravitreal antibiotics during globe repair?
In which cases of post-injection endophthalmitis should early vitrectomy be considered if there is little to no improvement 48 hours after a tap and inject and there is no organism isolated?
What factors influence your evaluation of surgical candidacy for persistent fetal vasculature, and how do you approach operative management?
Do you routinely recommend IV systemic antibiotic therapy in additional to intravitreal antibiotic therapy for exogenous bacterial endophthalmitis?
